Tag: Conference

HUDDLE: Cross-sectional study finds large gap between hypertension prevalence and awareness among former NFL athletes

Key Points: Little is known about the prevalence of cardiovascular risk factors…

Leah Kosyakovsky

Health 360x: Medical assistants more likely to complete training and remain in clinical research in community practices

Key Points: Research coordinators embedded in community-based practices can help ensure that…

Leah Kosyakovsky

HeLP: Behavioral interventions improve cardiac rehabilitation attendance among recently hospitalized patients with lower SES

Key Points: Low-SES patients are less likely to attend CR following hospitalization…

Leah Kosyakovsky

A Spirituality-Based Intervention Improves Blood Pressure Control and Central Hemodynamics: The FEEL Trial

Key Points: HTN is a leading cause of cardiovascular (CV) morbidity and…

Leah Kosyakovsky

No Benefit of Long-Term Beta-Blockers after MI with Preserved EF: REDUCE AMI Trial

Key Points -Beta blocker therapy in patients with acute MI is the…

Leah Kosyakovsky

TACT2: Chelation therapy with EDTA does not improve cardiovascular outcomes in post-MI patients with diabetes

Key Points: EDTA is a highly effective chelator of the ubiquitous pollutants…

Leah Kosyakovsky

Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Mellitus

Key Points: There is uncertainty determining who is likely to develop dysglycemia…

Leah Kosyakovsky

AEGIS-II: Apo A-I Infusions Did Not Reduce 90-Day MACE but Trended Towards Reduction in CV Death and MI

Key Points: Post-MI adverse cardiovascular events remain high despite robust evidence-based antiplatelet,…

Leah Kosyakovsky

A single SC dose of Zilebesiran reduced systolic blood pressure in uncontrolled hypertension: KARDIA-2

Key Points:  Zilebesiran is a subcutaneous injectable that targets hepatic angiotensinogen (AGT)…

Leah Kosyakovsky

Novel RNA interference therapeutic Zilebesiran results in dose-dependent sustained BP reduction

Key Points: Uncontrolled hypertension is a major public health concern, and this…

Leah Kosyakovsky

VERVE-101, a novel DNA-base editing medication, results in dose-dependent reductions in blood PCSK9 and LDL-C

Key Points: Despite the advent of PCSK9 inhibitors, the majority of patients…

Leah Kosyakovsky